pISSN 2636-0004
eISSN 2636-0012

Table. 1.

Clinical Trials of Systemic Treatments for Patients with Intermediate or Advanced Hepatocellular Carcinoma

Drug Mechanism Combination Trial identifier Phase
Sorafenib A protein kinase inhibitor Sorafenib + DEB-TACE vs DEB-TACE alone NCT00855218 2
Sorafenib + DEB-TACE vs DEB-TACE alone ISRCTN93375053 3
Sorafenib + TACE vs TACE alone NCT01217034 2
Sorafenib + HAIC NCT03722498 2
Brivanib VEGFR2 inhibitor Brivanib after TACE vs TACE alone NCT00908752 3
Orantinib VEGFR inhibitor Orantinib + TACE vs TACE alone NCT01465464 3
Camrelizumab + Apatinib Anti-PD-1 immune checkpoint inhibitor + Tyrosine kinase inhibitor Camrelizumab + Apatinib + TACE NCT04479527 2
Tremelimumab A monoclonal antibody against CTLA-4 Tremelimumab + RFA or TACE NCT01853618 1/2
Durvalumab + Tremelimumab Anti-PD-1 antibody + A monoclonal antibody against CTLA-4 Durvalumab + Tremelimumab after DEB-TACE NCT01853618 1/2
Durvalumab + Bevacizumab Anti-PD-1 antibody + Anti-VEGF antibody Durvalumab + Bevacizumab + DEB-TACE NCT03937830 2
Nivolumab Anti-PD-1 antibody Nivolumab + DEB-TACE NCT03143270 1
Nivolumab + TACE NCT03572582 2
Pembrolizumab Anti-PD-1 antibody Pembrolizumab after TACE NCT03397654 1/2
Immune killer cells Immune killer cells Immune killer cells + TACE vs TACE alone NCT03592706 2/3

DEB-TACE, drug-eluting beads using transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; VEGFR, vascular endothelial growth factor receptor; anti-PD-1, anti-programmed cell death protein-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; RFA, radiofrequency ablation; anti-VEGF, anti-vascular endothelial growth factor.

Int J Gastrointest Interv 2021;10:183~188 https://doi.org/10.18528/ijgii210046
© Int J Gastrointest Interv